Andrew Ko, MD

Brown University, Providence, RI, Sc.B., 1991, Applied Mathematics/Biology
Johns Hopkins School of Medicine, Baltimore, MD, M.D., 1995, Medicine
Board certified, Internal Medicine, 1998
Board certified, Medical Oncology, 2002

• 1995-1996
  Beth Israel Hospital (Boston, MA), intern, Department of Internal Medicine
• 1996-1998
  Beth Israel Hospital (Boston, MA), resident, Department of Internal Medicine
• 1998-2001
  Stanford University School of Medicine, fellow, Division of Medical Oncology
• 2001-present
  University of California at San Francisco, Clinical Instructor, Division of Hematology/Oncology
• 2003-2009
  University of California at San Francisco, Assistant Clinical Professor, Division of Hematology/Oncology
• 2009-present
  University of California at San Francisco, Associate Professor of Clinical Medicine, Division of Hematology/ Oncology

• 1987
  National Merit Scholarship
• 1988
  IBM Thomas J. Watson Memorial Scholarship
• 1990
  Sigma Xi, elected associate member
• 1991
  Departmental honors and Magna cum laude, Brown University
• 1993
  Alpha Omega Alpha, student essay competition honoree
• 1994
  Harry C. Saltzstein Prize in Medical Writing, Johns Hopkins School of Medicine
• 1995
  Medical Assistance Programs/Reader's Digest International Fellowship
• 2000
  Amgen National Oncology Fellows' Forum, selected for oral presentation
• 2000
  American Society of Clinical Oncology, Travel Award (meritorious abstract)
• 2001
  Digestive Disease Center Collaborative Postdoctoral Fellowship
• 2003
  UCSF Cancer Center Clinical Investigator Research Program award
• 2003
  American Society of Clinical Oncology Career Development Award
• 2007
  Joan Rombauer UCSF Endowed Fellowship
• 2008
  UCSF Kaiser Award for Excellence in Teaching in the Classroom Setting, nominee

• Original articles
• 1. Ko, AH. Repression, denial, backlash: sexually transmitted diseases in the People's Republic of China. Pharos 57(2): 11-15, Spring 1994.
• 2. Lee, SR, Ramos, SM, Ko, A, Masiello, D, Swanson, KD, Lu, ML, and Balk SP. AR and ER Interaction with a p21-Activated Kinase (PAK6). Mol Endocrinol 16(1):85-99, Jan 2002.
• 3. Harmon, EB*, Ko, AH*, and Kim, SK. Hedgehog signaling in gastrointestinal development and disease. Curr Mol Med 2(1):67-82, Jan-Feb 2002. (*equal contributors to this work)
• 4. Ko, AH, and Tempero, MA. Current and future strategies for combined modality therapy in pancreatic cancer. Curr Onc Rep 4(4):202-212, May 2002.
• 5. Ko, AH, and Yuen, AR. Clinical outcomes associated with very late relapses in diffuse large cell lymphoma. Leuk Lymphoma 43(9):1789-93, Sept 2002.
• 6. Ko, AH, Bergsland, EK, and Lee, GA. Tumor associated hypoglycemia from metastatic colorectal adenocarcinoma. Dig Dis Sci 48(1):192-196, Jan 2003.
• 7. Ko, AH, Hwang, J, Venook, AP, Abbruzzese, J, Bergsland, EK, and Tempero, MA. Serum CA 19-9 response as a surrogate for clinical outcome in patients with advanced pancreatic cancer treated with fixed-dose rate gemcitabine. Brit J Cancer 93(2):195-9, Jul 2005.
• 8. Ko, AH, and Tempero, MA. Treatment of metastatic pancreatic cancer. J Natl Compr Canc Netw., 3(5):627-36, Sep 2005.
• 9. Ko, AH, and Tempero, MA. Systemic therapy for pancreatic cancer. Semin Radiat Oncol, 15(4):245-53, Oct 2005.
• 10. Ko, AH, Dito, E, Schillinger, B, Venook, AP, Bergsland, EK, and Tempero, MA. A phase II study of gemcitabine given at fixed-dose rate infusion in combination with low-dose cisplatin for metastatic adenocarcinoma of the pancreas. J Clin Oncol, 24(3): 379-85, Jan 2006.
• 11. Ko, AH, Venook, AP, Quivey, J, Bergsland, EK, Dito, E, Schillinger, B, and Tempero, MA. A phase II study of fixed-dose rate gemcitabine plus low dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys., 68(3):809-16, Jul 2007.
• 12. Ko, AH. Future strategies for targeted therapies and tailored patient management in pancreatic cancer. Semin Oncol, 34(4):354-64, Aug 2007.
• 13. Ko, AH, Wang, F, and Holly, EA. Pancreatic cancer and medical history in a population-based case-control study in the San Francisco Bay Area, California. Cancer Causes Control, 18(8):809-19, Oct 2007.
• 14. Kavanagh B, Ko A, Venook A, Margolin K, Zeh H, Lotze M, Schillinger B, Liu W, Liu Y, Bercovici N, Bender J, Mills B, and Fong L. Vaccination of metastatic colorectal cancer patients with dendritic cells loaded with multiple class I peptides. J Immunother, 30(7):762-72, Oct 2007.
• 15. Ko, AH. Erlotinib in pancreatic cancer: a major breakthrough? Oncology, 21(14): 1706-09, Dec 2007.
• 16. Ko, AH, Dito, E, Schillinger, B, Venook, AP, Bergsland, EK, and Tempero, MA. Excess toxicity associated with docetaxel and irinotecan in patients with metastatic, gemcitabine-refractory pancreatic cancer: results of a phase II study. Cancer Invest, 26(1):47-52, Feb 2008.
• 17. Kelly, RK and Ko, AH. Erlotinib in the treatment of advanced pancreatic cancer. Biologics: Targets and Therapy, 2(1):1-13, March 2008.
• 18. Ko, AH. A daunting task: how to treat gemcitabine-refractory pancreatic cancer? Oncology, 22(10):1190-92, Sept 2008.
• 19. Ko, AH, Dito, E, Schillinger, B, Xu, Z, Venook, AP, Bergsland, EK, Wong, D, Scott, J, Hwang, J, and Tempero, MA. A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable? Invest New Drugs. 26(5):463-71, Oct 2008.
• 20. Wong, D*, Ko, AH*, Hwang, J, Venook, AP, Bergsland, EK, and Tempero, MA. Serum CA19-9 decline compared to radiographic response as a surrogate for clinical outcomes in patients with metastatic pancreatic cancer receiving fixed-dose rate gemcitabine. Pancreas, 37(3): 269-74, Oct 2008. (*equal contributors to this work)
• 21. Ko, AH and Tempero, MA. Personalized medicine for pancreatic cancer: a step in the right direction. Gastroenterology, 136(1):43-5, Jan 2009.
• 22. Chien, AJ, Illi, JA, Ko, AH, Korn, M, Fong, L, Chen, LM, Kashani-Sabet, M, Ryan, C, Rosenberg, J, Dubey, S, Small, EJ, Jahan, TM, Hylton, NM, Yeh, BM, Huang, Y, Koch, KM, Moasser, MM. A phase I dose-escalation study of a 2 day lapatinib chemosensitization pulse preceding weekly intravenous nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in patients with advanced solid maligancies. Clin Cancer Res, 15:5569-75. Sept 2009.
• 23. Ko, AH. Locally advanced pancreatic cancer: is there a role for radiation, and if so, when? Oncology, 23(12 suppl 4), November 2009.